DG-172 (hydrochloride)
目录号 : GC10190An orally available PPARβ/δ inverse agonist
Cas No.:1361504-77-9
Sample solution is provided at 25 µL, 10mM.
DG-172 (hydrochloride) is an orally available inverse agonist of PPARβ/δ with IC50 value of 27 nM [1].
Peroxisome proliferator-activated receptors (PPARs) are a member of the class II subset of nuclear receptors. The three PPAR subtypes (PPARα, PPARβ/δ, and PPARγ) regulate their target genes through binding to specific DNA elements (PPREs) as obligatory heterodimers with the retinoid X receptor. PPRE-bound PPARβ/δ complexes have functions in both transcriptional repression and transcriptional activation [1].
DG-172 is a novel PPARβ/δ-selective ligand and an orally available PPARβ/δ inverse agonist with IC50 value of 27 nM. In a cell-based assay, DG-172 efficiently antagonized ligand activation of PPARβ/δ. In C2C12 mouse myoblasts, DG-172 inhibited the expression of PPARβ/δ target gene Angptl4 with IC50 value of 9.5 nM. In WPMY-1 human myofibroblasts, DG-172 induced an enhanced recruitment of HDAC3 to the ANGPTL4 gene [1]. DG172 strongly increased GM-CSF-induced differentiation of primary BMCs into two specific populations, mature and immature dendritic cells (DCs) [2]. DG172 strongly inhibited the serum- and transforming growth factor b (TGFb)-induced invasion of MDA-MB-231 human breast cancer cells into a three-dimensional matrigel matrix [3].
References:
[1]. Lieber S, Scheer F, Meissner W, et al. (Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARβ/δ-selective ligand with inverse agonistic properties. J Med Chem. 2012 Mar 22;55(6):2858-68.
[2]. Lieber S, Scheer F, Finkernagel F, et al. The inverse agonist DG172 triggers a PPARβ/δ-independent myeloid lineage shift and promotes GM-CSF/IL-4-induced dendritic cell differentiation. Mol Pharmacol. 2015 Feb;87(2):162-73.
[3]. Adhikary T, Brandt DT, Kaddatz K, et al. Inverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion. Oncogene. 2013 Oct 31;32(44):5241-52.
Cell experiment: | The xCELLigence system is used for determining the changes in real time cell proliferation in response to activation of PPARD with an agonist (GW0742) or an inverse agonist (DG172) or the effect of inhibiting ERK signaling in TM4 cells[3]. |
References: [1]. Lieber S, et al. (Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARβ/δ-selective ligand with inverse agonistic properties. J Med Chem. 2012 Mar 22;55(6):2858-68. |
Cas No. | 1361504-77-9 | SDF | |
化学名 | 2-bromo-αZ-[[4-(4-methyl-1-piperazinyl)phenyl]methylene]-benzeneacetonitrile, dihydrochloride | ||
Canonical SMILES | CN1CCN(C2=CC=C(/C=C(C#N)/C3=C(Br)C=CC=C3)C=C2)CC1.Cl.Cl | ||
分子式 | C20H20BrN3 • 2HCl | 分子量 | 455.2 |
溶解度 | ≤20mg/ml in ethanol;25mg/ml in DMSO;25mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1968 mL | 10.9842 mL | 21.9684 mL |
5 mM | 0.4394 mL | 2.1968 mL | 4.3937 mL |
10 mM | 0.2197 mL | 1.0984 mL | 2.1968 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet